Navigation Links
Abbott's Investigational SIMCOR(R) Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
Date:11/4/2007

In the high-dose group, patients treated with SIMCOR combination therapy showed similar (non-inferior) improvements in non-HDL of 11 percent (1000 mg/40 mg) and 17 percent (2000 mg/40 mg) compared to a 10 percent improvement with 80 mg simvastatin therapy alone. Additionally, the high-dose combination group demonstrated significant improvements in HDL of 15 percent (1000 mg/40 mg) and 22 percent (2000 mg/40 mg) compared to a 1 percent decrease among those receiving 80 mg simvastatin monotherapy. Triglyceride levels among the high-dose combinations groups dropped 23 percent and 32 percent, respectively, in contrast to a 0.3 percent increase in those randomized to 80 mg simvastatin monotherapy.

Treatment with the four different doses of Niaspan combined with simvastatin for 24 weeks was well tolerated. There was no evidence for increased risk of hepatotoxicity or myopathy with the combination.

Treating Beyond LDL

Treatment of high cholesterol has long centered on the use of statins, including simvastatin, to lower LDL cholesterol, which has been the primary target of therapy. Clinical consensus now also emphasizes the importance of comprehensive cholesterol management, including management of HDL levels, in impacting cardiovascular risk.

In fact, a recent post-hoc analysis of 9,770 patients from the Treating to New Targets study, published in the New England Journal of Medicine, concluded HDL levels were predictive of major cardiovascular events in patients treated with statins, and also observed in patients with LDL levels below the National Cholesterol Education Program's most aggressive target of 70 mg/dL.

"We hope to make comprehensive cholesterol treatment more effective, more tolerable and more convenient for patients at risk for cardiovascular disease," said Eugene Sun, M.D., vice president of Global Clinical Development, Abbott.

About Niaspan

Available since 1997, Niaspan is the only FDA-approved, once-daily extended-r
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. New Drug Application Submitted for Investigational Antibiotic Doripenem
2. Astrazenecas Investigational Cancer Therapies Revealed at ASCO
3. Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke
4. Novel Investigational Drug May Help American Women Suffering from Breast Pain
5. Pancreatitis: Minimially Invasive Procedure Offers Long-Term Pain Relief
6. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
7. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
8. Roche offers HIV drug expertise to poor nations
9. Magnesium sulfate offers no help in migraine treatment
10. Drug Offers Hope for Alzheimers disease
11. Drug Firm Offers to Donate Smallpox Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2015)... Author Vincent N. Cefalu, Sr., MD. has always believed that ... of them aren’t aware of many products that are detrimental ... realize the dangers of physical inactivity and the many dangerous ... exist. There is also the fact that smokers ... In “ A Doctor’s Prescription for Longevity and Survival ” ...
(Date:5/25/2015)... The National Association of Professional ... inductee into its VIP Professional Woman of the Year ... leadership in dentistry. NAPW is the nation's leading networking ... members and over 200 operating local chapters. , ... of professional women,” said NAPW President Star Jones. “Her ...
(Date:5/25/2015)... 2015 The National Association of ... as a 2015-2016 inductee into its VIP Woman ... prestigious distinction for leadership in biomedical engineering. NAPW is ... boasting more than 700,000 members and over 200 operating ... this exceptional group of professional women," said NAPW President ...
(Date:5/25/2015)... York, New York (PRWEB) May 25, 2015 ... distributor of patented products, launches the Big Little Party ... to customize the perfect table that will suit their ... a whopping revenue of $646 billion this past year. ... a year industry" says Scott J. Cooper, CEO and ...
(Date:5/25/2015)... 24Hr HomeCare is proud to announce that David Allerby, ... Ryan Iwamoto, Co-Founder & CMO, are Finalists for the ... in Greater Los Angeles. The award is presented by ... performance, and a personal commitment to their communities. , ... success of our organization,” said Co-Founder & CEO, David ...
Breaking Medicine News(10 mins):Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 2Health News:New Book Reveals ‘A Doctor’s Prescription for Longevity and Survival’ 3Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lisa Ferrara, Ph.D., CEO of OrthoKinetic Technologies, Into its VIP Professional Woman of the Year Circle 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 3Health News:24Hr HomeCare Co-Founders Named Finalists for EY Entrepreneur of the Year 2015 Awards 2
... On Wednesday, September 14, Allan Coukell, a pharmacist and ... will testify before the Senate Health Education Labor and ... ensure the safety of the U.S. drug supply. ... now originate outside the U.S. Increasingly, Americans rely ...
... , FRIDAY, Sept. 9 (HealthDay News) -- One-third of ... metabolic disorder, a new study finds. This disorder ... naturally from many foods -- that has a foul, fishy ... disease that impairs the ability of an enzyme to metabolize ...
... human papillomavirus (HPV) vaccine Cervarix may be just as effective ... measures against cervical cancer, according to a new study published ... Cancer Institute . Across the globe, cervical cancer is ... 16 and 18 are a large contributor to the development ...
... Jenifer Goodwin HealthDay Reporter , THURSDAY, Sept. 8 ... or the death of a child in infancy have an ... study suggests. Researchers from the United Kingdom looked at ... stillborn child between 1971 and 2006 or whose child died ...
... each year with stage III or,locally advanced ... a viable,treatment option. Optimizing nonsurgical treatment strategies ... In an article published online,September 8, 2011 ... Institute, RTOG,researchers report that treating patients with ...
... HealthDay Reporter , THURSDAY, Sept. 8 (HealthDay News) -- ... rise, reaching 22.6 million, or 8.9 percent of the population, ... has largely been driven by more marijuana use, according to ... fact, in 2010 some 17.4 million Americans were using marijuana, ...
Cached Medicine News:Health News:Fewer than 3 doses of cervical cancer vaccine effective 2Health News:Losing Child in First Year Might Raise Early Death Risk for Parent 2Health News:Losing Child in First Year Might Raise Early Death Risk for Parent 3Health News:Concurrent chemo and radiation therepy improves long-term survival for inoperable stage III lung cancer 2Health News:More U.S. Adults Using Illegal Drugs: Report 2Health News:More U.S. Adults Using Illegal Drugs: Report 3
(Date:5/22/2015)... Fla. , May 22, 2015 ... Heart Institute recently traveled to Boston, ... procedure at the 2015 Heart Rhythm Society conference. ... together to focus on the ideas, people and ... Convergent is a hybrid, minimally invasive cardiac ...
(Date:5/22/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug development ... announced that J.J. Finkelstein , chief executive officer ... at two upcoming investor conferences. Mr. ... Annual Microcap Conference on Thursday May 28, 2015 in ... am EDT.  A webcast will be available at the ...
(Date:5/22/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... of the results of the Company,s 72-patient, placebo-controlled ... drops) for the treatment of dry eye patients ... ) model.  The exploratory study was completed in ... disseminated by the Company in a press release, ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: